SoftBank, the largest corporate venturer worldwide in recent years, is reportedly set to reduce its activity amid political and public market turmoil.
Category: News
Everli expands series C past $124m
The Pernod Ricard-backed round has been boosted by just over $24m from United Ventures, taking the grocery delivery service’s overall funding to over $143m.
ACA to land majority of BitFlyer
BitFlyer shareholders including Sekisui House have reportedly negotiated a majority sale of the cryptocurrency exchange for up to $370m.
Docker loads up $105m
Atlassian Ventures and Citi Ventures contributed to a series C round valuing the app development tool provider at $2.1bn.
Daily Deal Round Up: April 1, 2022
Smiths Medical and WuXi AppTec are exiting infusion pump developer Ivenix in an acquisition that could reach $240m, while AI software developer Syntiant raised $55m from investors including Renesas.
Gumi Cryptos Capital launches $110m second fund
The Gumi-backed venture firm has followed up its $21m debut fund and investments in the likes of OpenSea and Celsius Network with a sophomore vehicle.
Nova Labs surges to $200m series D
Alphabet, Goodyear, Liberty Global and Deutsche Telekom all took part in a round hiking the crypto IoT network developer’s valuation to $1.2bn
Modern Treasury magnifies series C to $135m
Salesforce Ventures helped top up the business payment platform developer’s series C round with a $50m extension.
Chief orders up $100m
Alphabet unit CapitalG led the female executive network’s series B round at a valuation of $1.1bn and is taking a board seat.
Daily Deal Round Up: March 31, 2022
Several corporates helped hydrogen refuelling service H2 Mobility Deutschland collect $122m while enterprise optimisation software developer Skan.ai closed a $40m Dell-led series B round
LayerZero Labs stacks up $135m
FTX Ventures, Uniswap, Coinbase Ventures and PayPal Ventures helped boost the blockchain technology developer’s valuation to $1bn.
Brightline shines on $105m series C
GV, Optum, Children’s Medical Center Corporation and Blue Cross Blue Shield of Massachusetts returned to take the behavioural health provider’s overall funding past $200m.
V-Bio Ventures finalises Fund 2
Venture capital firm V-Bio Ventures has reached the final close of its second fund, with Vanden Avenue Commodities among the limited partners.
SoftBank spearheads $100m Neuron23 round
The neurological disease treatment developer took its funding to over $213m, completing a series C round led by SoftBank Vision Fund 2.